|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Numerous experimental approaches are under way, and several encouraging drug classes, such as immune checkpoint inhibitors, poly(ADP-ribose) polymerase inhibitors, platinum agents, phosphatidylinositol-3-kinase pathway inhibitors, and androgen receptor inhibitors, are being investigated in TNBC.
|
27401886 |
2016 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies have shown it to antagonize estrogen receptor alpha (ERα) DNA binding, thereby preventing pro-proliferative gene transcription; whilst others have demonstrated AR to take on the mantle of a pseudo ERα particularly in the setting of triple negative breast cancer.
|
30416486 |
2018 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent efforts aimed at molecular characterisation of TNBCs have revealed various emerging therapeutic targets including PARP1, receptor and non-receptor tyrosine kinases, immune-checkpoints, androgen receptor and epigenetic proteins.
|
29202431 |
2018 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A poor DFS was observed for AR+/FOXA1+ tumors compared to other TNBCs (<i>p</i> = 0.0117).
|
31540486 |
2019 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We observed a TNBC subtype switch from the luminal androgen receptor to the basal-like subtype at acquired resistance.
|
28555173 |
2017 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype.
|
29940524 |
2018 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A meta-analysis of public gene expression databases indicated that ACSL4 expression is positively correlated with a unique subtype of triple negative breast cancer (TNBC), characterized by the absence of androgen receptor (AR) and therefore referred to as quadruple negative breast cancer (QNBC).
|
24155918 |
2013 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate that AR agonist DHT induces MSL TNBC breast cancer cells proliferation and inhibits apoptosis in vitro.
|
26938985 |
2016 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HER2<sup>+</sup> and triple-negative breast cancer cell lines were treated with AR antagonist plus anti-HER2 mAb trastuzumab or mTOR inhibitor everolimus.
|
28468774 |
2017 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer.
|
28512248 |
2017 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to assess the combined immunohistochemical expression of CK 5/6, AR, and p53 as a potential prognostic marker of adjuvant chemotherapy for patients with TNBC.
|
26009308 |
2016 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The frequency of grade 3 tumors was lower among AR-positive TNBC tumors compared to AR-negative tumors (40 vs 86.4%, p<0.001).
|
30570854 |
2019 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review highlights three of these recent trials of AR<sup>+</sup> TNBC and acknowledge ongoing research in this exciting area.
|
28766215 |
2017 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The biological association between mTOR activation and AR pathway suggests that there may exist a subgroup of TNBC in which the combination of both AR antagonism and mTOR inhibition should have a synergistic effect on cell growth and tumor progression.
|
27350136 |
2016 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also review the aberrant activated signals found in different subgroups of TNBC, including androgen receptor (AR) and PI3K/AKT/mTOR, Notch, Wnt/β-catenin, Hedge-hog, and TGF-β signaling pathways, which play essential roles in multiple development stages of TNBC.
|
29069872 |
2017 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Silencing BAG3 reduced Mcl-1 protein levels and overcame ABT-737 resistance in several of the cell lines, including triple-negative breast cancer (MDA-MB231) and androgen receptor-negative prostate cancer (PC3) cells.
|
23341456 |
2013 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed the diagnostic value of estrogen receptor, progesterone receptor, human epidermal growth factor receptor, thyroid transcription factor-1 (TTF1), Napsin A, mammaglobin, gross cystic disease fluid protein 15 (GCDFP15), Sry-related HMg-Box gene 10 (SOX10), GATA-binding protein 3 (GATA3), and androgen receptor in a series of 207 TNBC and 152 primary lung adenocarcinomas (LA).
|
30628926 |
2019 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers.
|
29880907 |
2018 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bivariate fit analysis demonstrated that QNBC (n = 224) significantly (P < .03) correlated with younger aged patients at initial biopsy compared to AR positive TNBC patients (n = 51).
|
30594038 |
2019 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen receptor has been associated with triple negative breast cancer pathogenesis, but its role in the different subtypes has not been clearly defined.
|
24505496 |
2014 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This phase II study evaluated the antitumor activity and safety of enzalutamide in patients with locally advanced or metastatic AR-positive TNBC.
|
29373071 |
2018 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, AR stimulates cellular proliferation in triple negative breast cancer (ERα -, PgR -, and HER-2-Neu -).
|
30210453 |
2018 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, our findings indicate that non-LAR subtypes of TNBC are AR dependent and, moreover, that enzalutamide is a promising targeted therapy for multiple molecular subtypes of AR(+) TNBC.
|
25713333 |
2015 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several molecular targets are being explored to target TNBC including androgen receptor, epidermal growth factor receptor (EGFR), poly(ADP-ribose) polymerase (PARP), and vascular endothelial growth factor (VEGF).
|
27137076 |
2017 |
|
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumoral heterogeneity and the presence of several subtypes of TNBC such as Basal like (BL)-1, BL-2, immune-modulatory, luminal androgen receptor, mesenchymal, and mesenchymal/stem like subtype and claudin low subtype, may explain some of the difficulties faced in managing this challenging disease subgroups.
|
27456662 |
2017 |